I discussed trading Dendreon options a few days ago. The company announced today that the Phase III study had met its endpoint and was a success. Dendreon will apply for licensure from the FDA in the fourth quarter and announce further details of the study at a conference 28th April.
The stock went from $7.50 to $20 when the market opened today. DNDN closed at $16.99.
Quite a run.
0 Responses
Stay in touch with the conversation, subscribe to the RSS feed for comments on this post.